Andreas Soerensen

Andreas Soerensen

Auto-generated profile, based on publicly available information

Andreas Soerensen

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2024 in Nature
Verified
Journal Article
Closed access
PDF file
EAElias Honerød Augestad
Elias Honerød Augestad
COChristina Holmboe Olesen
Christina Holmboe Olesen
CGChristina Grønberg
Christina Grønberg
ASAndreas Soerensen
Andreas Soerensen
RVRodrigo Velázquez-Moctezuma
Rodrigo Velázquez-Moctezuma
JPJannick Prentoe
Jannick Prentoe

15 November 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
JPJannick Prentoe
Jannick Prentoe
CJChristoph M. Janitzek
Christoph M. Janitzek
RVRodrigo Velázquez-Moctezuma
Rodrigo Velázquez-Moctezuma
ASAndreas Soerensen
Andreas Soerensen
TJThomas Jørgensen
Thomas Jørgensen
ABAdam F. Sander Bertelsen
Adam F. Sander Bertelsen
Development of B-cell-based hepatitis C virus (HCV) vaccines that induce broadly neutralizing antibodies (bNAbs) is hindered by extensive sequence diversity and low immunogenicity of envelope glycoprotein vaccine candidates, most notably soluble E2 (sE2). To overcome this, we employed two-component approaches using self-assembling virus-like particles (cVLPs; component 1), displaying monomeric or oligomeric forms of HCV sE2 (sE2mono or sE2oligo; component 2). Immunization studies were performed in BALB/c mice and the neutralizing capacity of vaccine-induced antibodies was tested in cultured-virus-neutralizations, using HCV of genotypes 1–6. sE2-cVLP vaccines induced significantly higher levels of NAbs (p = 0.0065) compared to corresponding sE2 vaccines. Additionally, sE2oligo-cVLP was superior to sE2mono-cVLP in inducing bNAbs. Interestingly, human monoclonal antibody AR2A had reduced binding in ELISA to sE2oligo-cVLP compared with sE2mono-cVLP and competition ELISA using mouse sera from vaccinated animals indicated that sE2oligo-cVLP induced significantly less non-bNAbs AR2A (p = 0.0043) and AR1B (p = 0.017). Thus, cVLP-displayed oligomeric sE2 shows promise as an HCV vaccine candidate.

27 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EAElias Honerød Augestad
Elias Honerød Augestad
COChristina Holmboe Olesen
Christina Holmboe Olesen
CGChristina Grønberg
Christina Grønberg
ASAndreas Soerensen
Andreas Soerensen
RVRodrigo Velázquez-Moctezuma
Rodrigo Velázquez-Moctezuma
JPJannick Prentoe
Jannick Prentoe
Worldwide, 58 million individuals suffer from chronic hepatitis C virus (HCV) infection, a primary driver of liver cancer. The HCV envelope proteins, E1 and E2, form a heterodimer, which is the target for neutralizing antibodies. Despite high-resolution structural models of partial heterodimer elements, the structural landscape of higher-order E1/E2 oligomers remains unexplored. We determined a ~3.5 Å cryo-electron microscopy structure of membrane-extracted HCV E1/E2 in a homodimeric arrangement. This structure includes detailed information on the homodimer interface, the E2-binding pocket for hypervariable region 1, antigenic site 412 conformation, and the organization of the E1/E2 transmembrane regions, including one internal to E1. This higher-order E1/E2 assembly could play a pivotal role in the design of novel vaccine antigens better mimicking E1/E2 complexes on the HCV particle.